Product Images Clopidogrel Bisulfate

Clopidogrel Tablets are used to reduce the risk of heart attack, stroke, and blood clots in people who have a high risk of developing them. This medication comes in the form of 75 mg tablets, with each tablet containing 97.875 mg of clopidogrel bisulfate, equivalent to 75 mg of clopidogrel. It is recommended to follow the dosage as per the product insert and take necessary precautions & warnings. This medicine is manufactured by Torrent Pharmaceuticals Ltd. and distributed by Major Pharmaceuticals and Cardinal Health. The storage temperature for these tablets is between 20°C to 25°C (68°F to 77°F) and should be kept in a tightly sealed container out of children's reach. RX ONLY - This Unit Dose package is not child-resistant, and for Institutional Use Only.*

The text appears to be a table showing the hazard ratio for patient baseline characteristics and on-study concomitant medications/interventions for the CURE study. The table includes subgroups such as age, gender, race, elevated cardiac enzymes, diabetes, previous MI, and previous stroke, as well as the number of patients in each subgroup who were treated with clopidogrel or placebo, and whether clopidogrel or placebo was favored. The table also includes a hazard ratio graph for the overall population.*

The text provides a table related to the hazard ratio for patient baseline characteristics and On-Study concomitant medications/interventions for the CURE study. It presents the number of patients and the percentage of those treated with clopidogrel and placebo along with the ratio statistics. The table evaluates the effect of different variables like heparin/LMWH, Aspirin, GPIIb/IlIa Antag, beta-blocker, and ACE inhibitor on the outcome.*

The text describes a figure, labeled "Figure 4: Cumulative Event Rates for Death in the COMMIT Study". The figure shows two groups, "2 Placebo" with 1645 deaths (8.1%) and "7 Clopidogrel" with 1726 deaths (7.5%). There is also a percentage labeled "proportional risk" and a number "5=0.03". There is a timeline labeled "Dars since randomization (up 10 28 davs)" and a note that all treated patients received aspirin.*

This appears to be a description of a clinical trial comparing the efficacy of a drug called "Clopidog" with a placebo. The trial included a total of 4,431 patients, with 2,310 in the placebo group and 2,121 in the Clopidog group. The percentage of patients who experienced an event (such as a heart attack or stroke) was 10.1% in the placebo group and 9.2% in the Clopidog group, resulting in a proportional risk reduction of 9% (with a p-value of 0.002). It is also noted that all treated patients received aspirin.*

The text presents a figure (Figure 6) that shows the effects of adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study. The table in the figure shows the percentage of patients who received Clopidogrel or Placebo, along with the number of patients in each subgroup based on Gender, Age at entry, Hours since onset, SBP (mmHg), Heart rate (bpm), and Fibrinolytic agent given. The figure also includes Odds Ratio with a 99% Confidence Interval for the Overall row.*

This is a graph displaying the cumulative event rate percentage of fatal or non-fatal vascular events over the course of 24 months of follow-up for clopidogrel bisulfate.*

This appears to be a table with measures related to the use of medication for stroke, MI (myocardial infarction), and PAD (peripheral artery disease). It includes data on the number of individuals receiving clopidogrel or aspirin, as well as the percentage of those groups. It also shows the hazard ratio for those on clopidogrel versus aspirin. Without additional context, it is unclear what the specific study or analysis is for.*

Not available.*